Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CSF Proteomics in Patients With Progressive Supranuclear Palsy

3 Jul 2024

Abstract excerpt

Background and Objectives Identification of fluid biomarkers for progressive supranuclear palsy (PSP) is critical to enhance therapeutic development. We implemented unbiased DNA aptamer (SOMAmer) proteomics to identify novel CSF PSP biomarkers. Methods This is a cross-sectional study in original (18 clinically diagnosed PSP-Richardson syndrome [PSP-RS], 28 cognitively healthy controls]), validation (23 PSP-RS, 26...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alzheimer's disease research and treatments
Share to Cerebral Palsy and Movement Disorders
Share to Parkinson's Disease Mechanisms and Treatments

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 38959435
DOI: 10.1212/wnl.0000000000209585

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CSF Proteomics in Patients With Progressive Supranuclear PalsyPMID 38959435Read ↗

Biomarker discovery in progressive supranuclear palsy from human cerebrospinal fluid using mass spectrometry-based proteomicsSemantic proximity Read ↗

A cerebrospinal fluid microRNA analysis: Progressive supranuclear palsySemantic proximity Read ↗

Identification of a novel proteomic Biomarker in Parkinson’s Disease: Discovery and Replication in Blood, brain and CSFSemantic proximity Read ↗

Identification of a possible proteomic biomarker in Parkinson’s disease: discovery and replication in blood, brain and cerebrospinal fluidSemantic proximity Read ↗

The diagnosis of progressive supranuclear palsy: current opinions and challenges.Semantic proximity Read ↗

Progressive supranuclear palsy: current approach and challenges to diagnosis and treatment.Semantic proximity Read ↗

Genetic, transcriptomic, histological, and biochemical analysis of progressive supranuclear palsy implicates glial activation and novel risk genesSemantic proximity Read ↗

Novel Therapeutic Targets and Biomarkers for the Treatment of Progressive Supranuclear PalsySemantic proximity Read ↗

Alzheimer’s disease and progressive supranuclear palsy share similar transcriptomic changes in distinct brain regionsSemantic proximity Read ↗

Genetic, transcriptomic, histological, and biochemical analysis of progressive supranuclear palsy implicates glial activation and novel risk genes.Semantic proximity Read ↗

Molecular Disease Stages of Oligodendrocytic and Neuronal Tau Burden in Progressive Supranuclear PalsySemantic proximity Read ↗

High-Plex CSF proteomics reveals a distinct vascular- immune signature in β-amyloid-negative corticobasal syndromeSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.